Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Epilepsia|February 27, 2007
Pharmacokinetics and drug interactions with zonisamideGraeme Sills, Martin BrodieNeurologic Clinics|October 21, 2022
Telemedicine and Epilepsy CareBruce Lavin, Cloe L Gray, Martin BrodieEpilepsy & Behavior : E&B|May 27, 2022
Sudden unexpected death in epilepsy (SUDEP): Definition, epidemiology, and significance of educationBoulenouar Mesraoua, Torbjorn Tomson, Martin Brodie, et al.Epilepsia|March 6, 2021
The road to a World Health Organization global action plan on epilepsy and other neurological disordersAlla Guekht, Martin Brodie, Mary Secco, et al.Clinical Pharmacokinetics|May 6, 2005
Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsyIsabelle Ragueneau-Majlessi, Rene H Levy, Martin Brodie, et al.BMJ Open|August 28, 2020
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)Silviya Balabanova, Claire Taylor, Graeme Sills, et al.Epilepsy & Behavior : E&B|October 9, 2025
Survey assessing the reproductive healthcare and information needs of women in Europe of childbearing age living with epilepsyGus A Baker, Martin Brodie, Erin Davies, et al.Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.Pageof 2